China Could Be Third Entry For Idiopathic Pulmonary Fibrosis Drug Pirfenidone
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Tokyo-headquartered GNI announced its Shanghai-based subsidiary-Shanghai Genomics has submitted a new drug application to Shanghai FDA for its TNF modulator F647 (pirfenidone) to treat patients with idiopathic pulmonary fibrosis (IPF)